(Q36627561)

15 August 2017

title

Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). (English)

1 reference

pneumococcal conjugate vaccine

15 August 2017

1 reference

1 reference

Daniel J Isaacman

1

1 reference

15 August 2017

Mark A Fletcher

2

1 reference

15 August 2017

Bernard Fritzell

3

1 reference

15 August 2017

Vincent Ciuryla

4

1 reference

15 August 2017

Jennifer Schranz

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

18 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

25

1 reference

15 August 2017

issue

13

1 reference

15 August 2017

page(s)

2420-2427

1 reference

The Spread of Bacterial Infection. The Problem of Herd-Immunity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Epidemiology of pertussis in Denmark: the impact of herd immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

The UK Hib vaccine experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

The Japanese experience with vaccinating schoolchildren against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

The pneumococcus: carriage, disease and conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

The potential indirect effect of conjugate pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Progress in the prevention of pneumococcal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Declining invasive pneumococcal disease in the U.S. elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Trends in Invasive Pneumococcal Disease—Associated Hospitalizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.011

10.1016/J.VACCINE.2006.09.011

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference